药物干预对慢性阻塞性肺疾病合并症的临床研究

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract ［Abstract］Objective To explore the clinical effect of different drug intervention on chronic obstructive pulmonary diseases（COPD）.M ethods 120 caseswith COPD in the stable period from September 2014 to December 2015 in our hospital were selected and divided into 4 groups according to the treatmentmeasures，30 cases in each group.The control group was given tiotropium bromide inhalation therapy，the atorvastatin treatment group was treated with atorvastatin oral therapy combined with tiotropium bromide inhalation therapy，the salmeterol and fluticasone treatment group was given salmeterol and fluticasone combined with tiotropium bromide inhalation therapy，the metoprolol treatment group was given metoprolol tablet oral therapy combined with tiotropium bromide inhalation therapy.Lung function，cat and mMRC scores，acute exacerbation frequency，the therapeutic effect of systemic comorbidities（cardiovascular and skeletal muscle atrophy，osteoporosis，depression and other）in each group within half a year was compared.Results The pulmonary function index of the salmeterol and fluticasone treatment group was higher than that of the control group，with significant difference　（P＜0.05）.The pulmonary function index of the atorvastatin group and themetoprolol group had no significant difference in comparison with that of the control group　（P＞0.05）.The symptom score in the salmeterol and fluticasone treatment group and the metoprolol treatment group was lower than that in the control group，acute exacerbation frequency withinhalf a year in the salmeterol and fluticasone treatment group and themetoprolol treatment group was less than that in the control group，with significant difference　（P＜0.05）.There was no significant difference in the symptom score and acute exacerbation frequency within half a year between the atorvastatin treatment group and the control group（P＞0.05）. The therapeutic effective rate of cardiovascular complications of the atorvastatin treatment group and the metoprolol treatment group was higher than that in the control group and the salmeterol and fluticasone treatment group，with statistically significant difference　（P＜0.05）.The therapeutic effective rate of skeletalmuscle atrophy comorbidity of the atorvastatin treatment group was higher than that of the other three groups，with significant difference（P＜0.05）.The therapeutic effective rate of osteoporosis and depression comorbidity of the atorvastatin treatment group，themetoprolol treatment group and the salmeterol and fluticasone treatment group showed no obvious decrease compared with that of the control group，without significant difference（P＞0.05）.Conclusion This study suggests that the combination ofmultiple drugs in the treatment of stable-stage COPD patientsmay achieve the best therapeutic effect of the disease and complications.

Key words： Drug intervention Chronic obstructive pulmonary disease Complication Therapeutic effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Jiang-qing
	DING Yue-mei
	LU Zhi-jun

Cite this article:

YU Jiang-qing,　DING Yue-mei,LU Zhi-jun. Clinical study of drug intervention on chronic obstructive pulmonary disease com plication[J]. 中国当代医药, 2016, 23(20): 21-24.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I20/21

［2］	中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）［J］.中华结核和呼吸杂志，2013，36（4）：255-264.
［7］	苗苗，李增燕，黄克武，等.，肺外合并症对稳定期慢性阻塞性肺疾病男性患者生活质量的影响［J］.山东医学，2014，54（47）：48-49.
［8］	Cazzola M，Matera MG，Rogliani P，et al.Treating systemic effects of COPD［J］.Trend S Pharmacol，2007，28（10）：544-550.
［9］	王巍伟，马迎民，方秋红，等，慢性阻塞性肺疾病住院患者死因与合并症分析［J］.北京医学，2012，34（11）：962-964.
［1］	Gan WQ，Man SF，Senthilselvan A，et al.Association between chronic obstructive pulmonary disease and systemic inflammation：a system atic review and a meta-analysis［J］. Thorax，2004，59（7）：574-580.
［3］	Dourado VZ，Tanni SE，Vale SA，et al.Systemic manifestations in chronic obstructive pulmonary disease［J］.J Bras Pneumol，2006，32（2）：161-171.
［4］	Celli BR，Cote CG，Marin JM，et al.The body-mass index，airflow obstruction，dyspnea，and exercise capacity index in chronic obstructive pulmonary disease［J］.N Engl JMed，2004，350（10）：1005-1012.
［5］	Casaburi R，ZuWallack R.Pulmonary rehabilitation formanagement of chronic obstructive pulmonary disease［J］.N Engl Med，2009，360（13）：1329-1335.
［6］	Hynninen KM，Breitve MH，Wiborg AB，et al.Psychological characteristics of patients with chronic obstruc tive pulmonary disease.a review［J］.Psychosom Res，2005，59（6）：429-443.
［10］	张素文，马露娜，黄静，等.综合干预对改善老年慢性阻塞性肺疾病患者生活质量的影响［J］.中国老年学杂志，2013，33（8）：1913.
［11］	杨光宇，孙培，黄茂，等.慢性阻塞性肺疾病合并症与急性加重期的关系［J］.江苏医药，2014，40（9）：1076-1079.
［12］	王少飞，张庆，张勃，等.戒烟干预对不同性别吸烟慢性阻塞性肺疾病患者临床症状及肺通气功能的影响［J］.中国全科医学，2013，16（1）：136-139.
［13］	李琛琛，王蕾.美托洛尔治疗慢性阻塞性肺疾病合并心血管疾病的疗效分析［J］.中国现代药物应用，2015，6（21）：137-138.
［14］	吴珍，宋国栋，王伟.他汀类药物对稳定期慢性阻塞性肺病治疗效果的Meta分析［J］.山东大学学报·医学版，2015，53（2）：12-18
［15］	Luo Z，Liu CT，Wu C G，et al.Efficacy and safety of tiotropium bromide in the treatment of chronic obstructive pulmonary disease—a multi-center randomized clinical trial［J］.Sichuan Da Xue Xue Bao Yi Xue Ban，2015，46 （3）：485-487.
［16］	戴然然，周新.慢性阻塞性肺疾病的合并症及期处理原则［J］上海医学，2014，37（7）：628-630.